BroadOak invested in CDI Labs, a provider of serological biomarker discovery services and monoclonal antibody manufacturing and validation services, to expand and scale antibody biomarker discovery platforms. The full press release is below.BALTIMORE, Jan. 9, 2023 /PRNewswire/ -- CDI Laboratories, Inc ("CDI Labs") announced today that it has received...
BroadOak portfolio company PBS Biotech, an innovative manufacturer of single-use bioreactors, has completed a $22 million financing that will be used to improve the company's products portfolio, expand its process development services capability, and increase customer support for global cell therapy clients. The full press release...
BroadOak portfolio company PhenoVista Biosciences, a leading provider of both custom and off-the-shelf imaging-based assay services, received an investment from Fujifilm's Life Sciences Corporate Venture Capital Fund to accelerate development of new high-content screening assay services using differentiated iPSCs. The full press release is below. TOKYO, December...
BioCare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) instrumentation and reagents, acquired BroadOak portfolio company Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics. The transaction brings an expansive molecular product...
BroadOak partnered with United BioChannels (UBC) to acquire ORFLO Technologies (ORFLO) in October 2022. ORFLO, a leading manufacturer of cell counting and characterization technologies, will be led by Varshal Davé, UBC's Managing Partner, who will assume the role of Chief Executive Officer. With over 3,000...
Flagship Biosciences hired industry veteran Tom Turi as Chief Scientific Officer. Tom will help grow the company’s spatial biology and biomarker analytics business and expand strategic partnerships supporting customers’ therapeutic development and clinical trials needs. BroadOak recently provided growth equity funding to Flagship Biosciences.Flagship's full...
BroadOak completed a growth equity investment in EmVenio Research, alongside members of the company’s management team in September 2022. EmVenio Research is a Decentralized Clinical Trials (DCT) company originally launched as part of Matrix Medical Network in 2020. In 2022, the company was spun out...
Following BroadOak’s growth equity investment in Flagship Biosciences, Flagship Biosciences has acquired Interpace Pharma Solutions, a provider of cytogenetic, molecular pathology, and genomic profiling solutions. Bill Snider and Aaron Fisher are joining the Board of Flagship Biosciences. The full press release is below. BROOMFIELD, Colo., Aug. 31,...
BroadOak joined Agilent Technologies, a global leader in life sciences and diagnostics, to increase its investment in Halo Labs as part of the company’s Series C round of growth financing.Halo Labs uses state-of-the-art optics and image processing to support drug development. The funding will help...
BroadOak invested in Microsize, a CDMO specializing in micronization and particle size control, as part of its launch as an independent business. The full press release is below. Microsize Launched as Independent Pharma Services Company Meets the Growing Need for US-Based API Solubility and Bioavailability Enhancement Services QUAKERTOWN, Pa....
Stay connected
Partner with BroadOak